Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2010
• Auteurs : Liqun LuoEugenio RodriguezKarim JerbiJean-Philippe LachauxJacques MartinerieMaurizio CorbettaGordon L ShulmanDaniele PiomelliGina G TurrigianoSacha B NelsonMarian JoëlsE Ronald de KloetFlorian HolsboerDavid M AmodioChris D FrithMichelle L BlockLuigi ZeccaJau-Shyong HongRobert DantzerKeith W KelleyA. D. Craig
• Organismes : Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Equipe NEMESIS - Centre de Recherches de l'Institut du Cerveau et de la Moelle épinière CHU Pitié-Salpêtrière [AP-HP] Department of Neuroscience and Pharmacology Neuronal Plasticity / Mouse Behaviour Laboratory of Integrative Immunophysiology
• Publié dans Nature Reviews Neuroscience le 01/11/2020

---

Résumé : To celebrate the first 10 years of Nature Reviews Neuroscience, we invited the authors of the most cited article of each year to look back on the state of their field of research at the time of publication and the impact their article has had, and to discuss the questions that might be answered in the next 10 years. This selection of highly cited articles provides interesting snapshots of the progress that has been made in diverse areas of neuroscience. They show the enormous influence of neuroimaging techniques and highlight concepts that have generated substantial interest in the past decade, such as neuroimmunology, social neuroscience and the 'network approach' to brain function. These advancements will pave the way for further exciting discoveries that lie ahead.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2010
• Auteurs : Laurent AbelSabine PlancoulaineEmmanuelle JouanguyShen-Ying ZhangNora MahfoufiNathalie NicolasVanessa Sancho-ShimizuAlexandre AlcaïsYiqi GuoAnnabelle CardonSoraya BoucheritDorothée ObachThomas ClozelLazaro LorenzoDaniel AmsallemPatrick BerquinThierry BlancCécile Bost-BruStéphane ChabrierBrigitte ChabrolEmmanuel CheuretOlivier DulacPhilippe EvrardBénédicte HéronLeila LazaroJosette ManciniJean-Michel PedespanFrançois RivierLouis ValléePierre LebonFlore RozenbergJean-Laurent CasanovaMarc Tardieu
• Organismes : Laboratory of Human Genetics of Infectious Diseases
• Publié dans The Journal of Pediatrics le 25/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2010
• Auteurs : Pierre-Yves OrainJean-François CaponFrédéric GloaguenPhilippe P. SchollhammerJean Talarmin
• Organismes : Chimie, Electrochimie Moléculaires et Chimie Analytique Chimie, Electrochimie Moléculaires et Chimie Analytique Chimie, Electrochimie Moléculaires et Chimie Analytique Chimie, Electrochimie Moléculaires et Chimie Analytique Chimie, Electrochimie Moléculaires et Chimie Analytique
• Publié dans International Journal of Hydrogen Energy le 31/10/2020

---

Résumé : The possibility of using hydrogenase models based on Fe2(μ-NRN) complexes was investigated. The use of benzo-[c]-cinnoline (BC = N2C12H8) bridge allows for an unprecedented control of the electron-transfer process in diiron complexes. We were able to modify the potential gap between the two one-electron reduction steps of [Fe2(BC)(CO)6] by changing the solvent properties. The catalyst exhibits modest catalytic activity for proton reduction. However, there is a considerable opportunity for improvement considering the wide range of azo-bridged diiron described in the literature.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2010
• Auteurs : Annie Prado-JeanPhilippe CouratierMichel Druet-CabanacPhilippe NubukpoLaurence Bernard-BourzeixPhilippe ThomasNicole DechampsHelene VideaudThierry DantoineJean-Pierre Clément
• Organismes : Neuroépidémiologie Tropicale et Comparée Centre de Mémoire de Ressources et de Recherches [Limoges] Neuroépidémiologie Tropicale et Comparée Service de Neurologie [CHU Limoges] Neuroépidémiologie Tropicale et Comparée Unité Fonctionnelle Registre Général des Cancers du Limousin Service de Santé au Travail [CHU Limoges] Neuroépidémiologie Tropicale et Comparée Centre de Mémoire de Ressources et de Recherches [Limoges] Hôpital Psychiatrique La Valette Centre de Mémoire de Ressources et de Recherches [Limoges] Centre de Mémoire de Ressources et de Recherches [Limoges] Centre de Mémoire de Ressources et de Recherches [Limoges] Centre de Mémoire de Ressources et de Recherches [Limoges] Centre de Mémoire de Ressources et de Recherches [Limoges] Service de Médecine Gériatrique [CHU Limoges] Neuroépidémiologie Tropicale et Comparée Centre de Mémoire de Ressources et de Recherches [Limoges] Service de Psychiatrie [CHU Limoges]
• Publié dans International Journal of Geriatric Psychiatry le 25/10/2020

---

Résumé : UNLABELLED: Behavioral and psychological symptoms in dementia (BPSD) are very common, with 90% of patients experiencing at least one during the course of the disease. One-third of persons with dementia have depressive symptoms, and concomitant BPSD are very likely. OBJECTIVE: This study aimed to characterize the psychological and behavioral manifestations of depression in patients with dementia. METHODS: We recruited patients with dementia from several nursing homes in the Limousin region of France. Depression was as diagnosed by the Cornell Scale for Depression in Dementia (CSDD) with a cut-off of 7, and BPSD were assessed using the Neuropsychiatric Inventory (NPI). RESULTS: Of 319 patients with dementia, 42.9% (n =137) were depressed and 75.9% (n = 242) had BPSD. All BPSD were significantly (p < 0.0001) more prevalent among depressed patients, but no significant differences were observed according to sex and age. The NPI showed that the most common additional symptoms in depressed patients were agitation (43.2%), anxiety (42.3%) and irritability (40.1%). Four NPI-based factors were indentified (63.9% of the common variance): factor 1 (disinhibition, irritability, agitation, anxiety), factor 2 (sleep disturbance, aberrant motor behavior, apathy), factor 3 (elation, hallucination, delirium) and the last with eating disorders. Depression in dementia patients was significantly associated with disinhibition, irritability, agitation, and anxiety. CONCLUSION: BPSD are common and a major problem. Before addressing them as isolated symptoms, it is important to consider comorbidity with depression in order to optimize the therapeutic approach.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2010
• Auteurs : Jean-Philippe EmpanaXavier JouvenFlorence Canouï-PoitrineGerald LucMuriel TaffletBernadette HaasDominique ArveilerJean FerrieresJean-Bernard RuidavetsMichèle MontayeJohn YarnellPierre MorangeFrank KeeAlun EvansPhilippe AmouyelPierre Ducimetiere
• Organismes : INSERM U258 AVENIR Team 'Epidemiology of sudden cardiac death'
• Publié dans Arteriosclerosis, Thrombosis, and Vascular Biology le 27/10/2020

---

Résumé : Objective— To examine prospectively the association of high-sensitivity C-reactive protein, interleukin 6, and fibrinogen with sudden death in asymptomatic European men. Methods and Results— Among the 9771 men from the Etude PRospective de l’Infarctus du Myocarde (PRIME) Study, 664 had a first coronary heart disease over 10 years, including 50 sudden deaths, 34 nonsudden coronary deaths, and 580 nonfatal coronary heart disease events. For each outcome, 2 matched controls, who were free of coronary heart disease at the index date, were randomly selected from the initial cohort (nested case control study design). There was a 3-fold increased risk (95% CI, 1.20 to 7.81) of sudden death between the upper and the lower third of interleukin 6 after adjustment for baseline confounders in conditional logistic regression analysis. Neither high-sensitivity C-reactive protein (hazard ratio third versus first tertile =1.27; 95% CI, 0.51 to 3.17) nor fibrinogen (hazard ratio third versus first tertile =1.90; 95% CI, 0.76 to 4.75) was associated with sudden death. For comparison, there was a 6-fold increased risk of nonsudden coronary death from the highest compared with the lowest tertile of fibrinogen and a trend toward an association with higher C-reactive protein and higher interleukin 6. All 3 inflammatory biomarkers were moderately, but significantly, associated with nonfatal coronary heart disease. Conclusion— Interleukin 6, but not high-sensitivity C-reactive protein or fibrinogen, is an independent predictor of sudden death in asymptomatic European men.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2010
• Auteurs : Béatrice LegouinMaud GayralPhilippe UriacJean-François CupifNicolas LevoinLoic ToupetPierre van de Weghe
• Organismes : Institut des Sciences Chimiques de Rennes Institut des Sciences Chimiques de Rennes Institut des Sciences Chimiques de Rennes Institut des Sciences Chimiques de Rennes Laboratoire Bioprojet Organométalliques et catalyse : chimie et électrochimie moléculaires Institut des Sciences Chimiques de Rennes
• Publié dans European Journal of Organic Chemistry le 22/10/2020

---

Résumé : A chiral molecular tweezer obtained from (+)-usnic acid placed in solution in the presence of various aromatic compounds afforded complexes with low association constants. Thus, the X-ray structure of assembly 3i is presented, where the guest is sandwiched between the two pincers of the tweezer. The association constants for various guests were determined through different methods. Finally, other tweezers with electron-rich aromatic aldehydes and ketones were prepared from (1R,2R)-1,2-diaminocyclohexane. The most interesting complexes were also confirmed through structural analysis, and the best results were obtained with 10-hydroxyphenanthrene-9-carbaldehyde (5i) as the aromatic moiety.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2010
• Auteurs : Gérald RaverotNathalie SturmFlorence de FraipontMarie MullerSylvie SalenavePhilippe CaronOlivier ChabrePhilippe ChansonChristine Cortet-RudelliRichard AssakerHenry DufourStéphan GaillardPatrick FrançoisEmmanuel JouanneauJean-Guy PassagiaMichèle BernierAurélie CornéliusDominique Figarella‑brangerJacqueline TrouillasFrançoise Borson-ChazotThierry Brue
• Organismes : Institut d'oncologie/développement Albert Bonniot de Grenoble Département d'anatomie et cythologie pathologique Institut d'oncologie/développement Albert Bonniot de Grenoble Laboratoire d'Imagerie Paramétrique Service Endocrinologie, maladies métaboliques et nutrition [CHU Toulouse] Département d'endocrino-diabétologie, maladies de la nutrition Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique Service d'Endocrinologie et Maladies de la reproduction Service de neurochirurgie [CHU Marseille] Centre de recherche en neurobiologie - neurophysiologie de Marseille Galaxies, Etoiles, Physique, Instrumentation Institut de Chimie des Substances Naturelles Service de pathologie et neuropathologie Centre de recherche en neurobiologie - neurophysiologie de Marseille
• Publié dans Journal of Clinical Endocrinology and Metabolism le 01/11/2020

---

Résumé : CONTEXT: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with temozolomide have been reported. Increased expression of O6-methylguanine-DNA-methyltranferase (MGMT) has been suggested to predict resistance to temozolomide. OBJECTIVES: The objective of the study was to describe the antitumoral efficacy and toxicity of temozolomide in patients with aggressive pituitary tumors or carcinomas and evaluate the possible prognostic value of MGMT promoter methylation and protein expression. PATIENTS: Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study. DESIGN: MGMT expression was assessed by immunohistochemistry and MGMT promoter methylation by pyrosequencing. RESULTS: Three of the eight patients (two ACTH adenomas and one PRL carcinoma) responded to temozolomide as demonstrated by significant tumor shrinkage and reduced hormone secretion. Three cycles of temozolomide were sufficient to identify treatment-responsive patients. Additional cycles did not improve treatment efficacy in those not responding, even when associated with carboplatin and vepeside. MGMT expression did not predict tumoral response to temozolomide because it was positive in one responder and negative in two nonresponders. Similarly, MGMT promoter methylation (three of seven tumors) did not predict clinical response. Toxicity remained mild in all patients. CONCLUSION: Temozolomide treatment may be an effective option for some aggressive pituitary tumors or carcinomas. Response to a trial of three cycles of treatment seems sufficient to identify responders and more reliable than patient MGMT status.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 30/09/2010
• Auteurs : Gilles MillatPatrice BouvagnetPhilippe ChevalierClaire DauphinPierre Simon JoukAntoine da CostaFabienne PrieurJean-Luc BressonLaurence FaivreJean-Christophe EicherNicolas ChassaingHervé CrehaletRaphaël PorcherClaire Rodriguez-LafrasseRobert Rousson
• Organismes : Laboratoire de Cardiogénétique Laboratoire Cardiogénétique Service de cardiologie RFMQ Service de Génétique Clinique Chromosomique et Moléculaire Service de Biochimie [Mondor] Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon) Service de Cardiologie [CHU de Dijon] Centre de Physiopathologie Toulouse Purpan Service de Biochimie et Biologie Moléculaire Service de Biostatistiques Centre Hospitalier Lyon Sud [CHU - HCL] Laboratoire de Cardiogénétique
• Publié dans European Journal of Medical Genetics le 22/10/2020

---

Résumé : Hypertrophic Cardiomyopathy (HCM), a common and clinically heterogeneous disease characterized by unexplained ventricular myocardial hypertrophy and a high risk of sudden cardiac death, is mostly caused by mutations in sarcomeric genes but modifiers genes may also modulate the phenotypic expression of HCM mutations. The aim of the current study was to report the frequency of single and multiple gene mutations in a large French cohort of HCM patients and to evaluate the influence of polymorphisms previously suggested to be potential disease modifiers in this myocardial pathology. We report the molecular screening of 192 unrelated HCM patients using denaturing high-performance liquid chromatography/sequencing analysis of the MYBPC3, MYH7, TNNT2 and TNNI3 genes. Genotyping of 6 gene polymorphisms previously reported as putative HCM modifiers (5 RAAS polymorphisms and TNF-α -308 G/A) was also performed. Seventy-five mutations were identified in 92 index patients (48%); 32 were novel. MYBPC3 mutations (25%) represent the most prevalent cause of inherited HCM whereas MYH7 mutations (12%) rank second in the pathogenesis. The onset age was older in patients carrying MYBPC3 mutations than in those with MYH7 mutations. The MYBPC3 IVS20-2A>G splice mutation was identified in 7% of our HCM population. Multiple gene mutations were identified in 9 probands (5%), highlighting the importance of screening other HCM-causing genes even after a first mutation has been identified, particularly in young patients with a severe phenotype. No single or cumulative genetic modifier effect could be evidenced in this HCM cohort.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 30/09/2010
• Auteurs : Amélie CharlesOlivier DarnéJean-François HoarauPhilippe Jean-Pierre
• Organismes : Audencia Business School

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 30/09/2010
• Auteurs : Jean-Pierre GangneuxC CamusB Philippe
• Organismes : Institut de recherche en santé, environnement et travail
• Publié dans Revue des Maladies Respiratoires le 31/10/2020

---

Source